Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1510MR)

This product GTTS-WQ1510MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1510MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9565MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ12664MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ2254MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ6394MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ3806MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ13017MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ14917MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7857MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-1223249
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW